May 4, 2026
Abstract, Surgical Film, Trial-in-Progress, Late-Breaking Shell Submission Closes
By June 10, 2026
Abstract, Surgical Film, Trial-in-Progress, Late-Breaking Shell Submission Notifications Sent
June 23, 2026
Registration Deadline for Abstract Presenters
Key Dates
The below deadlines are applicable to all IGCS 2026 abstract submission types – regular, case study, trial in progress, pragmatic trial concept, surgical film, late-breaking shell submission**. For more information on each submission type, please review the abstract guidelines.
| Abstract Submission Deadline | May 4, 2026 at 23:59 ET |
| Abstract Notifications | By June 10, 2026 |
| Registration Deadline for Abstract Presenters | June 23, 2026 |
**Late-breaking abstract authors must submit a shell abstract by the May 5 deadline. Please note that only accepted late-breaking shell submissions will be eligible to submit their final late-breaking abstracts by September 29. For more details, please review the LBA shell submission guidelines.
Abstract Submission Types
We are pleased to offer a wide variety of abstract submission types. Review the specifics of each type and submit your abstract by selecting the one most suitable for your research.
Regular Abstract
Accepted abstracts will be considered for all abstract presentation categories (oral, mini oral, featured poster, e-poster) based on their review scores and available slots in the program.
In addition to the general requirements for abstract submission (pages 8-9), all abstracts in this category must also adhere to the following submission requirements.
The text should be organized into four section headers as follows:
- Introduction: A brief statement about the purpose of the study and pertinent background.
- Methods: The method(s) of study or data collection employed.
- Results: A summary of study research including enough details to support your conclusions.
- Conclusion/Implications: A statement explaining the significance of your work and the implications for further research, practice and/or policy.
Abstracts should be clear, concise, and adhere to the word limit and submission requirements as outlined in the submission guidelines. High-quality submissions in this category will be considered for oral, short oral, featured poster or ePoster presentations during the annual meeting.
Trial-In-Progress
It is expected that trial-in-progress (TiP) abstracts present data on ongoing trials that have not reached any protocol-specified endpoints for analysis.
Accepted trial-in-progress abstract submissions will be considered for a featured poster presentation (if the trial is presented for the first time) or e-poster presentation.
In addition to the general requirements for abstract submission (pages 8-9), all TiP abstracts must also adhere to the following submission requirements.
The text should be organized into four section headers as follows:
- Introduction: A brief statement about the purpose of the trial and pertinent background.
- Objectives: A description of the primary and secondary endpoints of the trial.
- Methods: A summary of the study design, interventions, participant selection criteria, and statistical methods.
- Current Status & Future Directions: A brief outline of the trial progress, expected timeline for data analysis and potential clinical impact.
Eligibility:
- The NCT number (from ClinicalTrials.gov) or its national/regional equivalent, in accordance with the International Clinical Trials Registry Platform (ICTRP) standards, must be submitted alongside the abstract during the submission process within the Questionnaire section.
- TiP abstracts are applicable to trials in Phase I, Phase II, and Phase III, as well as combination trials involving multiple phases (e.g., Phase I/II).
- Recruitment must have already begun or have been completed by the trial-in-progress abstract submission deadline for IGCS 2026.
- TiP abstracts including results or preliminary data will not be considered.
- TiP abstracts submitted to IGCS 2025 are allowed for resubmission to IGCS 2026 if new/updated information is included.
Abstracts should be clear, concise, and adhere to the word limit and submission requirements as outlined in the submission guidelines. High-quality submissions in this category will be considered for oral, short oral, featured poster or ePoster presentations during the annual meeting.
Pragmatic Trial
Pragmatic trials are new and innovative trials answering key clinical questions in the field of gynecologic cancer that have previously not been tested. These are trials that are open to recruitment or have been approved and are expected to open shortly. These trials should have clearly defined outcomes of interest, including PFS, OS, ORR, etc. Background and methods should be clearly elucidated, along with an explanation of why the trial is novel and what clinical question should be answered. Trials in this category should be collaborative and geared toward low-resource settings.
Accepted pragmatic trial abstracts will be considered for featured poster or e-poster presentations based on their review scores and available slots in the program.
In addition to the general requirements for abstract submission (pages 8-9), all pragmatic trial abstracts must also adhere to the following submission requirements.
The text should be organized into five section headers as follows:
- Introduction: A brief statement about the purpose of the trial and pertinent background, including an outline of the innovative aspects.
- Objectives: A description of the primary and secondary endpoints of the trial. Objectives should focus on practical questions and outcomes, such as
o Treatment effectiveness in a broader, non-controlled clinical setting
o Health outcomes in diverse patient populations
o Cost-effectiveness or healthcare resource utilization in real-world practice - Trial Design: A description of the proposed design of the trial (e.g., randomized controlled trial, cohort study, etc.), including the pragmatic aspects that differentiate it from traditional trials.
- Feasibility and Implementation: A brief outline of the potential for implementing the trial in real-world settings. What challenges might arise in terms of patient recruitment, data collection, or logistics?
- Conclusion: A summary of the trial concept, reiterating its importance for advancing gynecological cancer care.
Abstracts should be clear, concise, and adhere to the word limit and submission requirements as outlined in the submission guidelines. High-quality submissions in this category will be considered for oral, short oral, featured poster or ePoster presentations during the annual meeting.
Surgical Films
Peer-reviewed surgical film submissions will be evaluated based on educational content and audio/visual quality. Accepted films will either be presented in the Featured Surgical Film session or will be included in the On-Demand Surgical Film Cinema.
All films must meet the following requirements:
- The film must be uploaded as an MP4 file within the abstract submission site. The file size should not exceed 500 MB.
- Films cannot exceed 8 minutes to be considered.
- Films must include either sound (recorded narration) or subtitles.
- Films must be free of commercial or product bias.
- Films must be uploaded in HD, in order to assure the best quality possible. The minimum dimensions accepted are 1280×720 (720p); 1920×1080 (1080p) and we suggest not compressing the file but leaving it in the original format. Please do not exceed the maximum length of 60 FPS.
- Films will be evaluated based on educational content and audio/visual quality.
- If the film is not set up as outlined above, this may prevent the assessment of the contents. The meeting organizers may contact you shortly after the submission deadline in case there are technical issues with the submitted film.
- Closer to the meeting, film presenters may be contacted with a request to send their films directly to the meeting organizers in MP4 format if selected for presentation.
- By submitting a film, the submitter acknowledges and agrees that, if the film is accepted for presentation at IGCS 2026, IGCS may include it in the official meeting proceedings, display it onsite as part of the IGCS 2026 scientific program, make it available on-demand in the IGCS Learning Portal following the meeting, and archive it within the IGCS Surgical Film Library.
Surgical Film Abstracts
The text should be organized into three section headers as follows:
- Introduction A brief statement about the purpose of the study and pertinent background.
- Description Short description of content (and surgical technique).
- Conclusion/Implications A statement explaining the significance of your work and the implications for further research, practice and/or policy.
Abstracts should be clear, concise, and adhere to the word limit and submission requirements as outlined in the submission guidelines. High-quality submissions in this category will be considered for oral, short oral, featured poster or ePoster presentations during the annual meeting.
Contact igcs_abstracts@kenes.com if you have questions about the surgical film submission and MP4 upload.
Late-Breaking Shell Submission
Late-breaking abstracts (LBAs) are reserved for high-impact research findings that were not available by the regular abstract submission deadline.
The IGCS 2026 Meeting will accept only original research showcasing innovative studies with compelling data in gynecologic oncology as late-breaking abstracts.
Accepted LBAs will be considered for oral or mini oral presentations based on their review scores and available slots in the program.
IMPORTANT: To ensure a fair review process, authors intending to submit an LBA must submit a shell abstract by the regular submission deadline.
Shell Abstract Submission
The shell abstract must include:
- Title of the abstract.
- Authors and their affiliations to the best of the submitter’s knowledge at the time of submission. The author list may be updated during the full abstract resubmission process if your shell submission is accepted.
- A brief explanation of the study and why it qualifies as late-breaking, included in the abstract introduction (e.g., key data not available by the regular deadline).
In addition to the general requirements for abstract submission (pages 8-9), all late-breaking submissions must also adhere to the following submission requirements.
The text of the LBA shell submission should be organized into four section headers as follows:
- Introduction: A brief statement about the purpose of the study and pertinent background.
- Methods: The method(s) of study or data collection employed.
- Preliminary Data or Expected Results: If available, include any preliminary findings, interim analyses, or a brief description of data collection progress. If results are unavailable, state when you expect them to be ready (e.g. “Data collection is ongoing, and results will be presented by …”).
- Significance and Impact: Highlight the potential implications of the study and why it is of high importance to the field.
Please note: Sections “Preliminary Data or Expected Results” and “Significance and Impact” will be removed from the final LBA submission for accepted shell abstracts and the corresponding authors will be requested to organize the text. Full LBA sections outlined in the submission guidelines.
Abstracts should be clear, concise, and adhere to the word limit and submission requirements as outlined in the submission guidelines. High-quality submissions in this category will be considered for oral, short oral, featured poster or ePoster presentations during the annual meeting.